MAO-B inhibitor

This page covers all MAO-B inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting MAO-B.

Targets

MAO-B

Marketed (1)

• MMI · Xiao-Ming Mao · Neurology
  MMI is a selective monoamine oxidase B (MAO-B) inhibitor.

Phase 3 pipeline (1)

• Safinamide (as add-on therapy) · Newron Pharmaceuticals SPA · Neurology
  Safinamide is a monoamine oxidase B (MAO-B) inhibitor that also has a weak inhibitory effect on monoamine oxidase A (MAO-A).